206989-54-0

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-4-(2-oxopropyl)piperidine is utilized as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its structural features allow for the creation of a wide range of biologically active molecules, enhancing the industry's capacity to address diverse medical needs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-Boc-4-(2-oxopropyl)piperidine serves as a valuable precursor for the design and synthesis of potential drug candidates. Its unique structure facilitates the exploration of novel chemical space, aiding researchers in the discovery of new compounds with therapeutic potential.
Used in Organic Synthesis:
1-Boc-4-(2-oxopropyl)piperidine is employed as a versatile building block in organic synthesis, enabling the construction of complex organic molecules. Its presence in the synthesis process can lead to the production of a variety of chemical entities, including those with applications beyond the pharmaceutical and medicinal chemistry sectors.

InChI:InChI=1/C13H23NO3/c1-10(15)9-11-5-7-14(8-6-11)12(16)17-13(2,3)4/h11H,5-9H2,1-4H3

Upstream product

• 75-16-1 methylmagnesium bromide 
• 416852-69-2 tert-butyl 4-{2-[methoxy(methyl)amino]-2-oxoethyl}piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 473795-40-3 1-(N-tert-butoxycarbonylpiperidin-4-ylidene)propan-2-one 

Downstream Products

• 473795-43-6 tert-Butyl 4-(3-Bromo-2-Oxopropyl)Piperidine-1-Carboxylate 
• 569667-97-6 4-(2-(chloromethyl)-2-oxoethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 473795-47-0 1-azabicyclo[3.2.2]nonan-3-one 

Relevant academic research and scientific papers

Preparation of novel azabicyclic amines and α7 nicotinic acetylcholine receptor activity of derived aryl amides

(Chemical Equation Presented) Three new azabicyclic amines, namely exo-3-amino-1-azabicyclo[3.2.1]octane, 3-amino-1-azabicyclo-[3.2.2]nonane and exo-6-amino-8-azabicyclo[3.2.1]octane, have been designed and prepared as isosteres of 3-aminoquinuclidine. Ar

BENZIMIDAZOLONE DERIVATIVES

This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I] ???[in which R1 and R2 stand for, e.g., hydrogen atoms; R3a, R3b, R4, R5 stand for, e.g., hydrogen atoms and alkyl groups; R6 stands for e.g., aryl or heteroaryl groups; A ring stands for 5- to 8-membered aliphatic heterocyclic ring containing one nitrogen atom; and Z stands for carbonyl group or sulfonyl group]. The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease; drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.

1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY

The invention provides compounds of Formula (I), wherein Azabicyclo is Formula (I, II, III, IV, V, VI, VII); W is Formula (m); where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.

Substituted-aryl compounds for treatment of disease

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.

Substituted azabicyclic moieties for the treatment of disease

The invention provides compounds of Formula I: 1wherein m1 is 0 or 1; m2 is 1 or 2; R1 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl; R2 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl, provided that when m1 is 1 at least one of R1 and R2 is —H; or a pharmaceutically acceptable salt, pharmaceutical composition, a pure enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of Formula I. These compounds may be in the form of pharmaceutical salts or compositions, and may be in pure enantiomeric form or may be racemic mixtures.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: wherein Azabicyclo is W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1-2 substitutents independently selected from R3. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.